Tag Archives: Accredo

Aetna Launches New Network to Cover New Gene Therapies for Rare Diseases

Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies

GBT’s Oxbryta® Accepted by FDA for Priority Review for Pediatric Sickle Cell Disease

The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years

JNJ’s UPTRAVI (selexipag) Receives FDA Approval for Intravenous Use in Adults

The FDA approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy

Evrysdi’s Positive News Beneficial to Both Genentech and PTC Therapeutics

Accredo is the only specialty pharmacy (SP) that prepares and ships Evrysdi directly to patients each month. Evrysdi is not available at retail pharmacies

Eton Pharmaceuticals’ ALKINDI® SPRINKLE is available exclusively through AnovoRx

AnovoRx’s focus is intentionally centered on the unique needs of patients with chronic diseases who rely on specialty and orphan drugs as well as manufacturers

Programs Covering the Cost of Gene Therapies Increase

Cell and gene therapies are revolutionizing the field of medicine by offering life-changing benefits to people with rare diseases and cancers

Express Scripts Divesting United Biosource

Express Scripts Divesting United Biosource. Express Scripts and Avista Capital Partners, a leading private equity firm, recently announced that Avista has signed a definitive agreement to acquire United BioSource (UBC), a wholly-owned subsidiary of Express Scripts Holding Company. Founded in 2003 and headquartered in Blue Bell, Pennsylvania, UBC is a leading provider of pharmaceutical and patient […]